A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biological effects, and impact on quality of life

J. Samuelsson, Hans Carl Hasselbalch, O. Bruserud, S. Temerinac, Y. Brandberg, Y. Merup, O. Linder, M. Bjorkholm, H.L. Pahl, G. Birgegard

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

OriginalsprogEngelsk
TidsskriftSyopa
Vol/bind106
Udgave nummer11
Sider (fra-til)2397-2405
ISSN0356-3081
StatusUdgivet - 2006

Citationsformater

Samuelsson, J., Hasselbalch, H. C., Bruserud, O., Temerinac, S., Brandberg, Y., Merup, Y., Linder, O., Bjorkholm, M., Pahl, H. L., & Birgegard, G. (2006). A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biological effects, and impact on quality of life. Syopa, 106(11), 2397-2405.